A Phase III, 12-week, Double-blind, Randomised, Parallel-group, Active-controlled, Multinational, Efficacy and Safety Study of Symbicort® Turbuhaler (R) 160/4.5 μg 2 Inhalations Twice Daily (Bid) Compared to Oxis (R) Turbuhaler (R) 4.5 μg 2 Inhalations Twice Daily (Bid) in Patients With Chronic Obstructive Pulmonary Disease

Trial Profile

A Phase III, 12-week, Double-blind, Randomised, Parallel-group, Active-controlled, Multinational, Efficacy and Safety Study of Symbicort® Turbuhaler (R) 160/4.5 μg 2 Inhalations Twice Daily (Bid) Compared to Oxis (R) Turbuhaler (R) 4.5 μg 2 Inhalations Twice Daily (Bid) in Patients With Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms SUMIRE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 23 May 2012 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met according to results presented at the 108th International Conference of the American Thoracic Society.
    • 17 Feb 2012 Actual initiation date (1 Mar 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top